

B-174 Transcending barriers to pain care in rural America:

A pragmatic comparative effectiveness trial of evidence-based, on-demand, digital behavioral treatments for chronic pain [833]

Brennan Spiegel, MD¹; Jeffrey R. Curtis, MD^{2,3}; Yashar Eshraghi, MD⁴; Maged Guirguis, MD⁴; Beth Darnall, PhD, MA⁵; Christine Rini, PhD⁶; Emily E. Holladay, MPH^{2,3}; Muskaan Mehra, MS¹; So Yung Choi, ScM¹; Sam Eberlein, MSHS¹

1 Cedars Sinai, Los Angeles, CA, United States of America, 2 University of Alabama at Birmingham, Birmingham, AL, United States of America, 3 Foundation for Advancing Science, Technology Education and Research, Birmingham, AL, United States of America, 4 University of Queensland Ochsner Medical School, New Orleans, LA, United States of America, 5 Stanford University School of Medicine, Palo Alto, CA, United States of America, 6 Northwestern University, Chicago, IL, United States of America

BACKGROUND

Evidence-based behavioral treatments for chronic pain are largely inaccessible, as are mental health providers, especially in rural areas.

OBJECTIVES

To conduct a decentralized randomized controlled trial comparing two evidence-based chronic pain management programs, testing virtual reality (VR) vs. traditional methods

- 3D immersive Skills-Based Virtual Reality (**EaseVRx+**)
- 2D interactive online pain coping skills training (**painTRAINER**)

METHODS

- Patients recruited from 4 sources (**Figure 1**)
- **Inclusion criteria:**
 - ICD-10 code associated with chronic pain
 - Primary ZIP code defined as rural
 - Age ≥13
 - ≥4 pain on 0-10 scale
 - No history of seizure (contraindication to VR)
- **1:1 randomization** to 3D VR vs. 2D web app
- **16 REDCap surveys** over **12 weeks**
- **Measured improvement in pain intensity** (primary outcome) between baseline and week 8; assessed minimal clinically important difference (MCID) of 2 points
- **Secondary outcomes included**
 - PROMIS anxiety and pain interference
 - Pain catastrophizing
 - Pain self-efficacy

Figure 1: Recruitment Sites





Figure 2: ITT Analysis of Pain Intensity Between Baseline and Week 8




ITT: Intent-to-treat. MCID: minimal clinically important difference.
Note: ITT analyses of the primary endpoint required responses to at least ≥4 of the 7 daily assessments.

RESULTS

- 330 participants (**169: EaseVRx+** and **161: painTRAINER**)
- **84.2%** participants completed trial, provided data for primary endpoint
- **Average pain score improved in both arms** (Mean[SD]: **1.22[1.48] units**)
- **No clinically significant difference:**
 - EaseVRx+ (22.9% achieving MCID ≥2)
 - PainTRAINER (32.0%) (p = 0.088) (**Figure 2**)
- **Baseline and week 8, mean (SD) changes for Ease VRx+ and painTRAINER**
 - PROMIS pain interference -3.2 (6.0) vs. -4.5 (6.3)
 - Pain catastrophizing -1.7 (3.2) vs. -1.8 (3.5)
 - PROMIS anxiety -0.6 (7.6) vs. -0.3 (7.6)
 - Pain self-efficacy for 0.6 (2.8) vs. 1.5 (2.7), respectively (**Figure 3**)

Figure 3: Mean Weekly Changes in Secondary Outcomes



CONCLUSIONS

- **Trial displays effectiveness** of two autonomous (self-paced) digital behavioral treatments for chronic pain anchored in virtual reality and traditional cognitive behavioral therapy approaches
- **EaseVRx+** and **painTRAINER** both shown as
 - **Effective and accessible** behavioral pain treatment for chronic pain
 - Could **improve health equity** in underserved populations for management of chronic pain

 **Cedars Sinai**
 **The University of Alabama at Birmingham.**

 **STANFORD UNIVERSITY**
 **Northwestern University**

 **faster**
 **Ochsner Health**

Disclosures: SYC, EEH, SE, CR, MM have nothing to disclose. BD is the Chief Science Advisor of AppliedVR. JRC has received support from AbbVie, Amgen, BMS, Janssen, Lilly, Novartis, Pfizer, Radius, Sanofi, Setpoint, AQTUAL, and UCB.

